# Shundong Cang

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/shundong-cang/

## Facts

| Field | Value |
| --- | --- |
| Citations | 7,675 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 38 |
| i10-index | 68 |
| Last Known Institution | Qingdao University |
| OpenAlex ID | https://openalex.org/A5039405375 |
| ORCID iD | 0000-0002-0146-7724 |
| Works | 180 |

## Researcher papers

- [Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study](https://scholariq.org/papers/sintilimab-plus-a-bevacizumab-biosimilar-ibi305-versus-sorafenib-in-unresectable/)
- [Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial](https://scholariq.org/papers/toripalimab-plus-chemotherapy-in-treatment-naive-advanced-esophageal-squamous/)
- [Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents](https://scholariq.org/papers/novel-histone-deacetylase-inhibitors-in-clinical-trials-as-anti-cancer-agents/)
- [Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)](https://scholariq.org/papers/efficacy-and-safety-of-sintilimab-plus-pemetrexed-and-platinum-as-first-line/)
- [Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer](https://scholariq.org/papers/sintilimab-plus-chemotherapy-for-unresectable-gastric-or-gastroesophageal/)
- [Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)](https://scholariq.org/papers/sintilimab-plus-platinum-and-gemcitabine-as-first-line-treatment-for-advanced-or/)
- [Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial](https://scholariq.org/papers/camrelizumab-plus-carboplatin-and-paclitaxel-as-first-line-treatment-for/)
- [Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer](https://scholariq.org/papers/third-generation-inhibitors-targeting-egfr-t790m-mutation-in-advanced-non-small/)
- [ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development](https://scholariq.org/papers/abt-199-venetoclax-and-bcl-2-inhibitors-in-clinical-development/)
- [Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis](https://scholariq.org/papers/exosomal-mir-4443-promotes-cisplatin-resistance-in-non-small-cell-lung-carcinoma/)
- [20P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients post osimertinib first line treatment failure: An interim analysis of GPS study](https://scholariq.org/papers/20p-genomic-profiles-in-egfr-mutant-locally-advanced-or-metastatic-nsclc/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)
- [RNA and protein synthesis mechanisms](https://scholariq.org/topics/rna-and-protein-synthesis-mechanisms/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Qingdao University](https://scholariq.org/institutions/qingdao-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.